We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Research Reports for NextEra Energy, Walgreens Boots & Southern Company
Read MoreHide Full Article
Wednesday, February 27, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NextEra Energy (NEE - Free Report) , Walgreens Boots (WBA - Free Report) and Southern Company (SO - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked NextEra Energy’s shares have outperformed the S&P 500 in the past year, gaining +24.1% vs +1.8%. The Zacks analyst thinks NextEra Energy’s investments to strengthen its infrastructure and ongoing capital projects, on completion, will help in serving the expanding customer base more efficiently. The expansion of business through strategic acquisitions positively impacted earnings.
However, the company’s nature of business is subject to complex and comprehensive federal, state and other regulations. Substantial investments are undertaken to ensure the safety of nuclear operations. That said, the risk of unplanned outages remains, which could derail its normal operations and impact profitability.
Shares of Walgreens Boots have underperformed the S&P 500 year to date, gaining +4.6% vs. +11.5%. Within Walgreen Boots' Retail Pharmacy USA division, the company has been making good progress on account of increasing prescription volume. The company is launching a new phase of transformational cost management to counteract margin pressure.
Walgreens has been gaining on account of strategic tie-ups as well. The Zacks analyst is optimistic about Walgreens Boots’ recent alliance with Alphabet’s life sciences and healthcare segment Verily. The company launching next-day prescription delivery service with FedEx buoys optimism.
Overall, the guidance for fiscal 2019 looks promising. However, tough market conditions, particularly in retail, have been leading to sluggishness in Retail Pharmacy International division. The ongoing generic drug inflation is hurting Walgreens' pharmacy margin.
Buy-ranked Southern Company's shares have outperformed the S&P 500 over the past six months, gaining +10.3% vs -3.6%. The Zacks analyst thinks Southern Company is one of the largest and best-managed electric utility holding companies in the United States, dominating the power business across the southeastern region.
With good rate base growth and constructive regulation, it is expected to generate steady earnings and dividend growth in the coming years through long-term power contracts. Additionally, SO's $12 billion AGL Resources buy has significantly increased its customer base and diversified offerings. However, continued timing and cost overrun issues over two large construction projects – Vogtle and Kemper – are major overhangs.
While the $25 billion Vogtle nuclear plant has gone well over budget and is years behind schedule, Southern's Kemper project suffered yet another setback with the suspension of all coal gasification operations amid additional cost burden. Hence, Southern Company warrants a cautious stance from the investors.
Other noteworthy reports we are featuring today include CSX Corporation (CSX - Free Report) , Ameriprise Financial (AMP - Free Report) and Macy's (M - Free Report) .
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Top Research Reports for NextEra Energy, Walgreens Boots & Southern Company
Wednesday, February 27, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NextEra Energy (NEE - Free Report) , Walgreens Boots (WBA - Free Report) and Southern Company (SO - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Buy-ranked NextEra Energy’s shares have outperformed the S&P 500 in the past year, gaining +24.1% vs +1.8%. The Zacks analyst thinks NextEra Energy’s investments to strengthen its infrastructure and ongoing capital projects, on completion, will help in serving the expanding customer base more efficiently. The expansion of business through strategic acquisitions positively impacted earnings.
However, the company’s nature of business is subject to complex and comprehensive federal, state and other regulations. Substantial investments are undertaken to ensure the safety of nuclear operations. That said, the risk of unplanned outages remains, which could derail its normal operations and impact profitability.
(You can read the full research report on NextEra Energy here >>>).
Shares of Walgreens Boots have underperformed the S&P 500 year to date, gaining +4.6% vs. +11.5%. Within Walgreen Boots' Retail Pharmacy USA division, the company has been making good progress on account of increasing prescription volume. The company is launching a new phase of transformational cost management to counteract margin pressure.
Walgreens has been gaining on account of strategic tie-ups as well. The Zacks analyst is optimistic about Walgreens Boots’ recent alliance with Alphabet’s life sciences and healthcare segment Verily. The company launching next-day prescription delivery service with FedEx buoys optimism.
Overall, the guidance for fiscal 2019 looks promising. However, tough market conditions, particularly in retail, have been leading to sluggishness in Retail Pharmacy International division. The ongoing generic drug inflation is hurting Walgreens' pharmacy margin.
(You can read the full research report on Walgreens Boots here >>>).
Buy-ranked Southern Company's shares have outperformed the S&P 500 over the past six months, gaining +10.3% vs -3.6%. The Zacks analyst thinks Southern Company is one of the largest and best-managed electric utility holding companies in the United States, dominating the power business across the southeastern region.
With good rate base growth and constructive regulation, it is expected to generate steady earnings and dividend growth in the coming years through long-term power contracts. Additionally, SO's $12 billion AGL Resources buy has significantly increased its customer base and diversified offerings. However, continued timing and cost overrun issues over two large construction projects – Vogtle and Kemper – are major overhangs.
While the $25 billion Vogtle nuclear plant has gone well over budget and is years behind schedule, Southern's Kemper project suffered yet another setback with the suspension of all coal gasification operations amid additional cost burden. Hence, Southern Company warrants a cautious stance from the investors.
(You can read the full research report on Southern Company here >>>).
Other noteworthy reports we are featuring today include CSX Corporation (CSX - Free Report) , Ameriprise Financial (AMP - Free Report) and Macy's (M - Free Report) .
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>